Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas
To explore mechanisms related to hormone resistance, three resistant variants of the MPA mouse breast cancer tumor model with low levels of progesterone receptor (PR) isoform A (PR-A)/high PR-B expression were developed by prolonged selective pressure with antiprogestins. The resistant phenotype of...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| Sumario: | To explore mechanisms related to hormone resistance, three resistant variants of the MPA mouse breast cancer tumor model with low levels of progesterone receptor (PR) isoform A (PR-A)/high PR-B expression were developed by prolonged selective pressure with antiprogestins. The resistant phenotype of one tumor line was reversed spontaneously after several consecutive passages in syngeneic BALB/c mice or by 17-b-estradiol or tamoxifen treatment, and this reversion was significantly associated with an increase in PR-A expression. The responsive parental tumors disclosed low activation of ERK and high activation of AKT; resistant tumors on the other hand, showed the opposite, and this was associated with a higher metastatic potential, that did not revert. This study shows for the first time in vivo a relationship between PR isoform expression and antiprogestin responsiveness, demonstrating that, whereas acquired resistance may be reversed, changes in kinase activation and metastatic potential are unidirectional associated with tumor progression. © Springer Science+Business Media, LLC. 2008. |
|---|---|
| Bibliografía: | Santen, R.J., Song, R.X., Zhang, Z., Kumar, R., Jeng, M.H., Masamura, A., Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity (2005) Endocr Relat Cancer, 12 (SUPPL. 1), pp. S61-S73. , doi: 10.1677/erc.1.01018 Osborne, C.K., Schiff, R., Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer (2003) Breast, 12, pp. 362-367. , doi:10.1016/S0960-9776(03)00137-1 Normanno, N., Di Maio, M., De Maio, E., De Luca, A., De Matteis, A., Giordano, A., Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer (2005) Endocr Relat Cancer, 12, pp. 721-747. , doi:10.1677/erc.1.00857 Haslam, S.Z., Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands (1988) Endocrinology, 122, pp. 464-470 Lydon, J.P., Demayo, F.J., Funk, C.R., Mani, S.K., Hughes, A.R., Montgomery Jr., C.A., Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities (1995) Genes Dev, 9, pp. 2266-2278. , doi:10.1101/gad.9.18.2266 Montero, G.G., Vanzulli, S.I., Cerliani, J.P., Bottino, M.C., Bolado, J., Vela, J., Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: Role of the host microenvironment (2007) Breast Cancer Res, 9, pp. R22. , doi:10.1186/bcr1660 Kordon, E.C., Molinolo, A.A., Pasqualini, C.D., Charreau, E.H., Pazos, P., Dran, G., Progesterone induction of mammary carcinomas in BALB/c female mice, Correlation between progestin dependence and morphology (1993) Breast Cancer Res Treat, 28, pp. 29-39. , doi:10.1007/BF00666353 Moore, M.R., A rationale for inhibiting progesterone-related pathways to combat breast cancer (2004) Curr Cancer Drug Targets, 4, pp. 183-189. , doi:10.2174/1568009043481515 Lanari, C., Molinolo, A.A., Pasqualini, C.D., Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice (1986) Cancer Lett, 33, pp. 215-223. , doi:10.1016/0304-3835(86)90027-3 Lanari, C., Molinolo, A., Diverse activation pathways for the progesterone receptor: Possible implications for breast biology and cancer (2002) Breast Cancer Res, 4, pp. 240-243. , doi:10.1186/bcr539 Aldaz, C.M., Liao, Q.Y., Labate, M., Johnston, D.A., Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene (1996) Carcinogenesis, 17, pp. 2069-2072. , doi:10.1093/carcin/17.9.2069 Health Initiative, W., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial (2002) JAMA, 288, pp. 321-333. , doi:10.1001/jama.288.3.321 Beral, V., Breast cancer and hormone-replacement therapy in the Million Women Study (2003) Lancet, 362, pp. 419-427. , doi: 10.1016/S0140-6736(03)14596-5 Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B (1990) EMBO J, 9, pp. 1603-1614 Leo, J.C., Lin, V.C., The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner (2008) Int J Cancer, 122, pp. 230-243. , doi:10.1002/ijc.23081 Richer, J.K., Jacobsen, B.M., Manning, N.G., Abel, M.G., Wolf, D.M., Horwitz, K.B., Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells (2002) J Biol Chem, 277, pp. 5209-5218. , doi:10.1074/jbc.M110090200 Shyamala, G., Yang, X., Silberstein, G., Barcellos-Hoff, M.H., Dale, E., Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands (1998) Proc Natl Acad Sci USA, 95, pp. 696-701. , doi:10.1073/pnas.95.2.696 Shyamala, G., Yang, X., Cardiff, R.D., Dale, E., Impact of progesterone receptor on cell-fate decisions during mammary gland development (2000) Proc Natl Acad Sci USA, 97, pp. 3044-3049. , doi: 10.1073/pnas.97.7.3044 Mulac-Jericevic, B., Lydon, J.P., Demayo, F.J., Conneely, O.M., Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform (2003) Proc Natl Acad Sci USA, 100, pp. 9744-9749. , doi:10.1073/pnas.1732707100 Hopp, T.A., Weiss, H.L., Hilsenbeck, S.G., Cui, Y., Allred, D.C., Horwitz, K.B., Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates (2004) Clin Cancer Res, 10, pp. 2751-2760. , doi:10.1158/1078-0432.CCR-03-0141 Long, B.J., Jelovac, D., Handratta, V., Thiantanawat, A., MacPherson, N., Ragaz, J., Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model (2004) J Natl Cancer Inst, 96, pp. 456-465 MacEdo, L.F., Sabnis, G.J., Goloubeva, O.G., Brodie, A., Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model (2008) Cancer Res, 68, pp. 3516-3522. , doi: 10.1158/0008-5472.CAN-07-6807 Beeram, M., Tan, Q.T., Tekmal, R.R., Russell, D., Middleton, A., Degraffenried, L.A., Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling (2007) Ann Oncol, 18, pp. 1323-1328. , doi:10.1093/annonc/mdm170 Boylan, M., Van Den Berg, H.W., Lynch, M., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: Growth stimulation in the presence of tamoxifen (1998) Ann Oncol, 9, pp. 205-211. , doi:10.1023/A:1008241804078 Lin, X., Yu, Y., Zhao, H., Zhang, Y., Manela, J., Tonetti, D.A., Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model (2006) Carcinogenesis, 27, pp. 1538-1546. , doi:10.1093/carcin/bgl002 Naundorf, H., Fichtner, I., Saul, G.J., Haensch, W., Buttner, B., Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice (1993) J Cancer Res Clin Oncol, 119, pp. 652-656. , doi:10.1007/BF01215983 Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N., Pasqualini, C.D., Mouse mammary tumors induced by medroxyprogesterone acetate: Immunohistochemistry and hormonal receptors (1987) J Natl Cancer Inst, 79, pp. 1341-1350 Vanzulli, S.I., Soldati, R., Meiss, R., Colombo, L., Molinolo, A.A., Lanari, C., Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression (2005) Carcinogenesis, 26, pp. 1055-1063. , doi:10.1093/carcin/bgi060 Simian, M., Molinolo, A., Lanari, C., Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression (2006) Am J Pathol, 168, pp. 270-279. , doi:10.2353/ajpath.2006. 050012 Fabris, V.T., Benavides, F., Conti, C., Merani, S., Lanari, C., Cytogenetic findings, Trp53 mutations, and hormone responsiveness in a medroxyprogesterone acetate induced murine breast cancer model (2005) Cancer Genet Cytogenet, 161, pp. 130-139. , doi: 10.1016/j.cancergencyto.2005.02.008 Institute of Laboratory Animal Resources CoLSNRC (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC; Kordon, E.C., Guerra, F., Molinolo, A.A., Charreau, E.H., Pasqualini, C.D., Pazos, P., Effect of sialoadenectomy on medroxyprogesterone-acetate-induced mammary carcinogenesis in BALB/c mice. Correlation between histology and epidermalgrowth- factor receptor content (1994) Int J Cancer, 59, pp. 196-203. , doi: 10.1002/ijc.2910590210 Helguero, L.A., Viegas, M., Asaithamby, A., Shyamala, G., Lanari, C., Molinolo, A.A., Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment (2003) Breast Cancer Res Treat, 79, pp. 379-390. , doi:10.1023/A:1024029826248 Vanzulli, S., Efeyan, A., Benavides, F., Helguero, L., Peters, G., Shen, J., P21, p27 and p53 in estrogen and antiprogestininduced tumor regression of experimental mouse mammary ductal carcinomas (2002) Carcinogenesis, 23, pp. 749-757. , doi:10.1093/carcin/23.5.749 Liu, W., Bagaitkar, J., Watabe, K., Roles of AKT signal in breast cancer (2007) Front Biosci, 12, pp. 4011-4019. , doi:10.2741/2367 Montecchia, M.F., Lamb, C., Molinolo, A.A., Luthy, I.A., Pazos, P., Charreau, E., Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas (1999) J Steroid Biochem Mol Biol, 68, pp. 11-21. , doi: 10.1016/S0960-0760(98)00166-6 Aupperlee, M.D., Smith, K.T., Kariagina, A., Haslam, S.Z., Progesterone receptor isoforms A and B: Temporal and spatial differences in expression during murine mammary gland development (2005) Endocrinology, 146, pp. 3577-3588. , doi:10.1210/en.2005-0346 Horwitz, K.B., Tung, L., Takimoto, G.S., Novel mechanisms of antiprogestin action (1996) Acta Oncol, 35, pp. 129-140. , doi:10.3109/02841869609098493 Lamb, C.A., Helguero, L.A., Giulianelli, S., Soldati, R., Vanzulli, S.I., Molinolo, A., Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice (2005) Breast Cancer Res, 7, pp. R1111-R1121. , doi:10.1186/bcr1345 Dran, G., Luthy, I.A., Molinolo, A.A., Charreau, E.H., Pasqualini, C.D., Lanari, C., Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma (1995) Breast Cancer Res Treat, 35, pp. 173-186. , doi:10.1007/BF00668207 Arruvito, L., Giulianelli, S., Flores, A.C., Paladino, N., Barboza, M., Lanari, C., NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis (2008) J Immunol, 180, pp. 5746-5753 Ingle, J.N., Ahmann, D.L., Green, S.J., Edmonson, J.H., Bisel, H.F., Kvols, L.K., Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer (1981) N Engl J Med, 304, pp. 16-21 Carter, A.C., Sedransk, N., Kelley, R.M., Ansfield, F.J., Ravdin, R.G., Talley, R.W., Potter, N.R., Diethylstilbestrol recommended dosages for different categories of breast cancer patients (1977) Report of the Cooperative Breast Cancer Group. JAMA, 237, pp. 2079-2085 Beex, L., Pieters, G., Smals, A., Koenders, A., Benraad, T., Kloppenborg, P., Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer (1981) Cancer Treat Rep, 65, pp. 179-185 Lonning, P.E., Taylor, P.D., Anker, G., Iddon, J., Wie, L., Jorgensen, L.M., High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy (2001) Breast Cancer Res Treat, 67, pp. 111-116. , doi:10.1023/A:1010619225209 Conneely, O.M., Jericevic, B.M., Lydon, J.P., Progesterone receptors in mammary gland development and tumorigenesis (2003) J Mammary Gland Biol Neoplasia, 8, pp. 205-214. , doi:10.1023/A1025952924864 Weigel, R.J., Deconinck, E.C., Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma (1993) Cancer Res, 53, pp. 3472-3474 Ferguson, A.T., Lapidus, R.G., Davidson, N.E., Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression (1998) Oncogene, 17, pp. 577-583. , doi: 10.1038/sj.onc.1201961 Martin, L.A., Farmer, I., Johnston, S.R., Ali, S., Dowsett, M., Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation (2005) Endocr Relat Cancer, 12 (SUPPL. 1), pp. S75-S84. , doi:10.1677/erc.1.01023 Brodie, A., Sabnis, G., Jelovac, D., Aromatase and breast cancer (2006) J Steroid Biochem Mol Biol, 102, pp. 97-102. , doi:10.1016/j. jsbmb.2006.09.002 Qiu, M., Olsen, A., Faivre, E., Horwitz, K.B., Lange, C.A., Mitogen activated protein kinase regulates nuclear association of human progesterone receptors (2003) Mol Endocrinol, 17, pp. 628-642. , doi: 10.1210/me.2002-0378 Labriola, L., Salatino, M., Proietti, C.J., Pecci, A., Coso, O.A., Kornblihtt, A.R., Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells (2003) Mol Cell Biol, 23, pp. 1095-1111. , doi:10.1128/MCB.23.3.1095-1111.2003 Faivre, E.J., Daniel, A.R., Hillard, C.J., Lange, C.A., Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors (2008) Mol Endocrinol, 22, pp. 823-837. , doi:10.1210/me.2007-0437 Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Activation of PI3K/Akt signaling and hormone resistance in breast cancer (2006) Breast Cancer, 13, pp. 137-144. , doi: 10.2325/jbcs.13.137 Toker, A., Yoeli-Lerner, M., Akt signaling and cancer: Surviving but not moving on (2006) Cancer Res, 66, pp. 3963-3966. , doi: 10.1158/0008-5472.CAN-06-0743 |
| ISSN: | 01676806 |
| DOI: | 10.1007/s10549-008-0150-y |